Atai: Following The Path That Spravato Laid And Moving Beyond It
Jason Najum talks to Srinivas Rao, CEO of Atai Life Sciences, a biotech company focused on mental health and psychedelic compounds.
Psychedelics-Focused Compass Pathways Has Established Itself As 'Credible CNS Biotechnology Company,' Analyst Says
Compass Pathways gains Stifel's Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression study data expected in 2025-2026.
Avesta Ketamine and Wellness Opens Clinic in Columbia, Maryland
Avesta Ketamine and Wellness (Avesta), the leading provider of monitored ketamine care in the Washington, D.C., Maryland and ...
Compass Pathways Plc (CMPS) Q4 2024 Earnings Call Transcript
Compass Pathways Plc (NASDAQ: CMPS) Q4 2024 Earnings Call Feb 27, 2025, 8:00 a.m. ET ...
Compass Pathways rises 10% as Stifel initiates with a buy
Stifel has initiated Compass Pathways (NASDAQ:CMPS) with a buy rating saying that stakeholders are starting to agree there is ...